Project Name: The Clatterbridge Cancer Centre early breast cancer SACT Service Redesign
Project Summary:
This Collaborative Working Project (“CWP”) aims to optimise workforce capacity within the breast oncology service to deliver a new SACT remote follow-up service for early breast cancer patients.
Within the scope of this CWP, the dedicated workforce of a Band 8a Clinical Pharmacist, a Band 0.8 Advanced Nurse Practitioner (ANP) a Band 6 SACT Nurse and a Band 4 Coordinator will work for a duration of 23 months clinical activity (the duration of the project will be for 32 months) on a temporary basis, with the intention of substantiating the roles through the development and submission of a business case as part of the milestone delivery.
Through the implementation of this CWP, the aim is to achieve the following;
- Safeguard the future capacity of the Breast Cancer Service at The Clatterbridge Cancer Centre.
- Redesigning patient pathway in a cohesive way to engage and upskill non-medical prescribers in a most efficient way to ensure patients are treated by the most appropriate healthcare professional, releasing consultant capacity.
- Ensure early breast patients are seen, reviewed, and treated in an efficient and timely manner.
- Utilise ePROMs (electronic Patient Reported Outcomes Measures) to assist in triaging patients to relevant services.
In addition, by incorporating a pathway mapping exercise using established Process Mapping methodologies, once six months clinical activity is achieved, a map and profile of the new breast early breast SACT pathway workflow design can be assessed to identify challenges and further opportunities for pathway sustainability and improvement.
Over the duration of this collaborative working project, it is estimated that up to an additional 900 patients will utilise the new eBC SACT clinic, generating an additional 4800 patient appointments.
Expected Benefits:
ANTICIPATED BENEFITS FOR PATIENTS:
- Faster access to equitable, consistent, and standardised care.
- Increased access to education on BC and side effects of therapies to improve treatment adherence and consequently patients’ outcomes, supported by a personalised care plan.
- Reduce patient waits in the clinic given extra capacity created by new workforce role.
- Reduced unplanned medical reviews and admissions.
- More streamlined pathway to improve the patient’s experience and limit visits to the hospital
- Increased and dedicated workforce will improve patient uptake of ePROMs
ANTICIPATED BENEFITS FOR THE ORGANISATION:
- Increase the overall quality of care and improve equity of access to specialist care for patients with BC requiring treatment initiation, evaluation and monitoring.
- Provide a single point of contact for a dedicated cohort of patients, thereby reducing the potential for unplanned calls being received by the wider clinical team.
- Free up consultant capacity for clinical activities within the Breast Cancer Service that are unique to their skillset.
- Reduce use of emergency triage line and unplanned admissions.
- Workforce efficiency and optimisation by removing administrative burden from clinical staff and coordinating patient care
- Increased clinic efficiency by ensuring all up to date tests results are available at the right time
- Increase the overall quality of care and improve equity of access to specialist care for patients with BC requiring treatment initiation, evaluation, and monitoring
ANTICIPATED BENEFITS FOR NOVARTIS
- Better understanding of overall HCP and patient needs
- Optimal use of medicines in line with local/national guidance (including Novartis medicines) in appropriate patients.
- Ethical, professional, and transparent relationship between Novartis and the Healthcare Organisations
Start Date & Duration: February 2026 for 32 months
FA-11593952 | February 2026